Drug intelligence / Profile preview

HuCo Heart

Development stage: Preclinical
Lead developer: eGenesis
Modality: Gene Therapies

Overview

HuCo Heart is a gene editing therapy developed by eGenesis for the prevention of cardiac transplant rejection. It is designed to address immune system diseases, specifically targeting the challenge of organ rejection in heart transplantation. The therapy leverages advanced gene editing technologies to modify donor organs or cells, aiming to reduce or eliminate the need for long-term immunosuppression in transplant recipients. As of May 2025, its highest development status is preclinical.

Brand names: HuCo Heart
Other names: HuCo Heart

Beyond the preview

Go deeper on HuCo Heart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HuCo Heart.

Explore the full profile